Exagen Management

Management criteria checks 2/4

Exagen's CEO is John Aballi, appointed in Oct 2022, has a tenure of 1.58 years. total yearly compensation is $931.95K, comprised of 56.3% salary and 43.7% bonuses, including company stock and options. directly owns 0.94% of the company’s shares, worth €212.03K. The average tenure of the management team and the board of directors is 1.6 years and 4.4 years respectively.

Key information

John Aballi

Chief executive officer

US$932.0k

Total compensation

CEO salary percentage	56.3%
CEO tenure	1.6yrs
CEO ownership	0.9%
Management average tenure	1.6yrs
Board average tenure	4.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has John Aballi's remuneration changed compared to Exagen's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$932k	US$525k	-US$24m
Sep 30 2023	n/a	n/a	-US$32m
Jun 30 2023	n/a	n/a	-US$35m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$1m	US$111k	-US$47m

Compensation vs Market: John's total compensation ($USD931.95K) is above average for companies of similar size in the German market ($USD400.67K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

CEO

John Aballi (38 yo)

1.6yrs

Tenure

US$931,950

Compensation

Mr. John Aballi serves as President, Chief Executive Officer and Director at Exagen Inc. since October 17, 2022. Most recently he served as SVP, General Manager, Urology & CLIA COO at Veracyte Inc. Mr. Aba...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Tina Nova	Executive Chairman of the Board of Directors	4.8yrs	US$132.81k	0% $ 0
John Aballi	CEO, President & Director	1.6yrs	US$931.95k	0.94% $ 212.0k
Kamal Adawi	CFO & Corporate Secretary	6.9yrs	US$915.09k	0.30% $ 68.3k
Ryan Douglas	Investors Relations Officer	no data	no data	no data
John Wegener	Senior Vice President of Sales and Marketing	10.5yrs	no data	no data
Andrew Concoff	Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board	1.6yrs	no data	no data
Michael Nerenberg	Chief Medical Officer	less than a year	no data	no data

1.6yrs

Average Tenure

54yo

Average Age

Experienced Management: E08A's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Tina Nova	Executive Chairman of the Board of Directors	4.8yrs	US$132.81k	0% $ 0
John Aballi	CEO, President & Director	1.6yrs	US$931.95k	0.94% $ 212.0k
Andrew Concoff	Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board	4.4yrs	no data	no data
Kenneth Bloom	Member of Breast Cancer Advisory Board	no data	no data	no data
Mark Pegram	Member of Breast Cancer Advisory Board	no data	no data	no data
Bruce Robertson	Independent Director	4.8yrs	US$33.75k	no data
Thomas Williams	Member of Breast Cancer Advisory Board	no data	no data	no data
Brian Birk	Independent Director	15.8yrs	US$80.70k	0% $ 0
Michael Press	Member of Breast Cancer Advisory Board	no data	no data	no data
Lyndsay Harris	Member of Breast Cancer Advisory Board	no data	no data	no data
Arthur Weinstein	Chairman of Scientific Advisory Board	4.4yrs	US$130.00k	no data
Frank Stokes	Independent Director	2.9yrs	US$82.70k	0% $ 0

4.4yrs

Average Tenure

64yo

Average Age

Experienced Board: E08A's board of directors are considered experienced (4.4 years average tenure).

Exagen Management

Management criteria checks 2/4

Key information

Recent management updates

Exagen Inc., Annual General Meeting, Jun 10, 2024

Exagen Inc. Announces Changes in Board of Directors

CEO, President & Director recently sold €56k worth of stock

Exagen Inc. Appoints Paul Kim as Class II Director

Exagen Inc. Announces Board Changes

Exagen Inc. Announces Executive Changes

Recent updates

Exagen Inc. to Report Q1, 2024 Results on May 13, 2024

Exagen Inc., Annual General Meeting, Jun 10, 2024

Exagen Inc. Announces Changes in Board of Directors

Full year 2023 earnings released: US$1.34 loss per share (vs US$2.77 loss in FY 2022)

New major risk - Revenue and earnings growth

Exagen Inc. to Report Q4, 2023 Results on Mar 18, 2024

Exagen Inc. Reaffirms Earnings Guidance for the Full Year Ended December 31, 2023

Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.47 loss in 3Q 2022)

Exagen Inc. to Report Q3, 2023 Results on Nov 13, 2023

CEO, President & Director recently sold €56k worth of stock

New minor risk - Financial position

Second quarter 2023 earnings released: US$0.28 loss per share (vs US$0.86 loss in 2Q 2022)

New major risk - Share price stability

Exagen Inc. to Report Q2, 2023 Results on Aug 07, 2023

Exagen Inc. Appoints Paul Kim as Class II Director

First quarter 2023 earnings released: US$0.44 loss per share (vs US$0.60 loss in 1Q 2022)

Full year 2022 earnings released: US$2.77 loss per share (vs US$1.68 loss in FY 2021)

Exagen Inc. Announces Board Changes

Exagen Inc. Announces Executive Changes

Exagen Inc. Increases Revenue Guidance for 2022

Exagen Inc. announced delayed 10-Q filing

Exagen Inc. to Report Q3, 2022 Results on Nov 14, 2022

Exagen Inc. Appoints John Aballi as President

Exagen Inc. Appoints Andrew L. Concoff as Chief Innovation Officer

Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

Second quarter 2022 earnings released: US$0.78 loss per share (vs US$0.38 loss in 2Q 2021)

Exagen Inc. Provides Revenue Guidance for the Year of 2022

Exagen Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings released: US$0.60 loss per share (vs US$0.48 loss in 1Q 2021)

Exagen Inc. Revises Revenue Guidance for the Full Year of 2022

Exagen Inc. to Report Q1, 2022 Results on May 11, 2022

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.34 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.38 loss per share (vs US$0.27 loss in 2Q 2020)

Exagen Inc. Announces the Publication of Their Latest Clinical Utility Study in Lupus & Science Medicine

Independent Director Jeffrey Elliott has left the company

Independent Director Jeffrey Elliott has left the company

First quarter 2021 earnings released: US$0.48 loss per share (vs US$0.44 loss in 1Q 2020)

Exagen Inc. Provides Earnings Guidance for the Fiscal Year 2021

Full year 2020 earnings released: US$1.32 loss per share (vs US$8.46 loss in FY 2019)

Exagen Inc. Provides Revenue Guidance for the Full Year 2021

New 90-day high: €17.10

Exagen Inc. to Report Q4, 2020 Results on Mar 16, 2021

New 90-day high: €15.20

New 90-day high: €14.70

Exagen Inc. Partners with Boston’s Tufts Medical Center to Offer AVISE Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases

Exagen Inc. Partners with St. Charles Health System, Inc. to Offer AVISE Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases

New 90-day low: €9.20

Exagen Inc. Extends its Collaboration Agreement with GlaxoSmithKline plc

Third quarter 2020 earnings released: US$0.34 loss per share

Revenue beats expectations

Exagen Inc. Announces Resignation of Chet Burrell from the Board, Effective December 31, 2020

Exagen Inc. Announces Study to Evaluate Emergence of Autoimmune Diseases After COVID-19 Infection in Collaboration with Brigham and Women’s Hospital

Exagen Inc. to Report Q3, 2020 Results on Nov 10, 2020

Exagen Inc. Announces the Publication of Study Evaluating the Economic Benefits AVISE® Lupus Testing

Exagen Inc. Announces Agreement with Provider Network of America Expanding Access for AVISE® Tests to 8 Million Members

New 90-day low: €9.15

Exagen Inc. Appoints Wendy Johnson as a Class III Director, and to Audit Committee Effective as of October 1, 2020

Exagen Launches Test to Aid in the Detection of ANCA-Associated Vasculitis (AAV)

New 90-day high - €13.90

Exagen Inc. to Report Q2, 2020 Results on Jul 28, 2020

Exagen Inc.(NasdaqGM:XGN) dropped from Russell Microcap Value Index

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members